Stockreport

Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants

Eupraxia Pharmaceuticals Inc.  (EPRX) 
PDF VICTORIA, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage bi [Read more]